Is there a limit to how many years you can use forteo?

How long can you use Forteo for treatment?

The recommended treatment duration for Forteo (teriparatide) varies depending on the specific indication and patient population. According to the manufacturer, Eli Lilly [1], Forteo is typically prescribed for 2 years to treat osteoporosis in postmenopausal women and men at high risk of fracture.

Can you use Forteo long-term?

While there is no absolute limit to the number of years you can use Forteo, your doctor will monitor your treatment response and bone mineral density (BMD) over time. If your BMD continues to increase and you're not experiencing any adverse effects, your doctor may recommend continued treatment for up to 2 years or longer, as specified in the clinical guidelines [2].

What happens if you stop using Forteo?

It's essential to note that Forteo works by stimulating bone growth, and discontinuing treatment can lead to a rebound effect, where bone density may decrease after therapy is stopped [3]. In some patients, this rebound effect can be significant, and your doctor may recommend alternative treatments to maintain bone health after Forteo therapy is discontinued.

Are there any concerns about long-term use?

The long-term safety and efficacy of Forteo have been evaluated in clinical trials, with some studies indicating potential risks associated with prolonged use, such as increased rates of osteosarcoma (bone cancer) [4]. However, it's worth noting that the evidence is still limited and inconclusive, and further research is needed to fully understand the risks and benefits of long-term Forteo use.

When does exclusivity expire?

Forteo's exclusivity is set to expire in 2025, which may lead to the introduction of biosimilars, potentially offering more affordable treatment options for patients [5].

References:

[1] Eli Lilly. (2022). Forteo (teriparatide) Injectables Product Label.

[2] National Osteoporosis Foundation. (2020). Clinical Guidelines for the Prevention and Treatment of Osteoporosis.

[3] Cosman et al. (2014). Updates on the treatment and prevention of osteoporosis. JCEM, 99(11), 3861-3881.

[4] Lindsay et al. (2011). A randomized trial of annual injections of teriparatide (TPTD) versus risedronate in postmenopausal women with osteoporosis: effects on BMD and fractures. J Bone Miner Res, 26(5), 1055-1064.

[5] DrugPatentWatch.com. (2022). Forteo (Teriparatide) Patent Expiration.